G. Steven Burrill
An introduction to Burrill Venture Capital
Flash required to view this video. Download the latest version here
G. Steven BurrillNews
Biotech takes a beating in market meltdown October 01, 2008 | Press Release
Biotech outperforms market in May June 02, 2008 | Press Release
Biotech Treads Water in April May 01, 2008 | Press Release
See all NewsVenture Capital
Nora Therapeutics is an early stage specialty biopharmaceuticals company focusing on commercializing therapeutics to address issues in reproductive health. Based on medical research in immunology and supported by a strong intellectual property position, Nora’s lead therapeutic candidates are FDA-approved products repurposed to improve the likelihood for term pregnancy in women who suffer from repeated assisted reproductive failure (i.e., in vitro fertilization or IVF) and recurrent miscarriage.
